Business Context and Reporting Period
CF Acquisition Corp. VIII, a special purpose acquisition company (SPAC), filed this Form 8-K on October 11, 2022, reporting events occurring primarily on October 9, 2022. The filing relates to the proposed combination with XBP Europe, Inc., a wholly owned subsidiary of BTC International Holdings, Inc. The transaction is the basis for the future XBP Global Holdings, Inc. entity referenced in the request metadata.
Transaction and Key Terms
- CF VIII, Sierra Merger Sub, Parent, and XBP Europe entered into an Agreement and Plan of Merger dated October 9, 2022.
- Merger Sub will merge with and into XBP Europe, with XBP Europe surviving as a direct wholly owned subsidiary of CF VIII.
- Each XBP Europe share will be exchanged for CF VIII Class A common stock based on an equity value of $220 million less XBP Europe closing indebtedness, divided by $10.00, plus 1,330,650 shares.
- At closing, CF VIII intends to amend its charter and change its name to XBP Europe Holdings, Inc.
- CF VIII agreed to take commercially reasonable actions so that the post-closing board consists of seven individuals designated by XBP Europe, with Par Chadha as chair.
- Parent waived any right, title, interest, or claim to CF VIII’s trust account.
Financial Metrics, Liquidity, and Capital Structure
The filing does not provide a clear value for revenue, profit or loss, cash flow, operating margins, cash balances, liquidity, or debt other than the transaction formula’s reference to XBP Europe closing indebtedness. The filing is primarily a transaction announcement and does not include current-period financial statements.
- The Sponsor agreed to forfeit 733,400 Class B common shares at closing.
- The Sponsor agreed not to redeem certain shares in connection with the transaction and to waive anti-dilution rights relating to its Class B shares.
- Outstanding Sponsor loans may be repaid in Class A common stock valued at $10.00 per share, subject to the Merger Agreement.
- Parent securities received or held immediately following closing will generally be subject to a lock-up until the earlier of one year after closing or a qualifying liquidation, merger, or similar transaction.
Material Changes Versus the Prior Comparable Period
No comparable-period operating or financial data is presented. The material development is the execution of the definitive merger agreement and related support and lock-up agreements.
Conditions, Timing, Outlook, and Risks
- Closing is subject to CF VIII stockholder approval, required governmental and regulatory approvals, filing of a definitive proxy statement, compliance with applicable law, effectiveness of ancillary agreements, and completion of the Delayed Contribution.
- Additional conditions include delivery of PCAOB-compliant audited financial statements for XBP Europe and its subsidiaries, the absence of a material adverse effect, execution of tax-sharing and services agreements involving Exela Technologies, Inc., and approval for listing of the shares to be issued.
- The Merger Agreement may be terminated in specified circumstances, including failure to obtain stockholder approval, failure to deliver required financial statements, certain Nasdaq listing failures, uncured breaches, legal prohibitions, or failure to close by June 30, 2023. An automatic extension may apply through September 30, 2023, subject to the agreement’s terms.
- No termination fee or expense reimbursement is required upon termination, although parties remain liable for willful and material breaches before termination.
- CF VIII and XBP Europe expected to prepare and file a proxy statement and provide CF VIII stockholders redemption rights under the SPAC’s governing documents and IPO prospectus.
- Risks identified include failure to complete the transaction, inability to satisfy closing conditions, litigation, Nasdaq listing risks, securities-price volatility, transaction costs, failure to realize anticipated benefits, customer and employee retention, inability to achieve or maintain profitability or generate cash, changing market conditions, COVID-19 effects, European energy shortages, regulatory changes, and difficulty managing growth.
Most Important Facts for Investors to Verify
- Review the definitive proxy statement and subsequent SEC filings for the final transaction terms, valuation, dilution, redemption levels, and required stockholder approvals.
- Verify XBP Europe’s PCAOB-compliant audited financial statements, including revenue, profitability, cash flow, debt, and liquidity.
- Confirm the amount of XBP Europe closing indebtedness, which directly affects the number of shares issued under the transaction formula.
- Monitor whether all regulatory, listing, ancillary-agreement, and Delayed Contribution conditions are satisfied.
- Assess the effects of CF VIII stockholder redemptions, Sponsor share forfeiture, Sponsor loan conversion, and Parent lock-up provisions on the post-closing capital structure.
- Distinguish forward-looking statements and investor-presentation projections from audited historical results; the filing states that such statements are subject to substantial risks and uncertainties.